Sequential Administration of Carbon Nanotubes and Near-Infrared Radiation for the Treatment of Gliomas

Santos, Tiago; Fang, Xin; Chen, Meng-Tse; Jhaveri, Niyati; Gundersen, M.A.; Zhou, Chongwu; Pagnini, P; Hofman, Florence M.; Chen, Thomas C.

doi:10.3389/fonc.2014.00180

Cited by 33 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To minimize cytotoxicity due to MWCNTs, only low doses (5 or 10 μg/ml) were used. Consistent with previous reports using this model 14 , both 5 and 10 μg/ml MWCNT-treatment significantly increased cell death compared to NIR alone (Supplemental Fig. S3).…”

Section: Resultssupporting

confidence: 92%

Photothermal Therapy of Glioblastoma Multiforme Using Multiwalled Carbon Nanotubes Optimized for Diffusion in Extracellular Space

Eldridge

Bernish

Fahrenholtz

et al. 2016

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and most lethal primary brain tumor with a 5 year overall survival rate of approximately 5%. Currently, no therapy is curative and all have significant side effects. Focal thermal ablative therapies are being investigated as a new therapeutic approach. Such therapies can be enhanced using nanotechnology. Carbon nanotube mediated thermal therapy (CNMTT) uses lasers that emit near infrared radiation to excite carbon nanotubes (CNTs) localized to the tumor to generate heat needed for thermal ablation. Clinical translation of CNMTT for GBM will require development of effective strategies to deliver CNTs to tumors, clear structure-activity and structure-toxicity evaluation, and an understanding of the effects of inherent and acquired thermotolerance on the efficacy of treatment. In our studies, we show that a dense coating of phospholipid-poly(ethylene glycol) on multiwalled CNTs (MWCNTS) allows for better diffusion through brain phantoms, while maintaining the ability to achieve ablative temperatures after laser exposure. Phospholipid-poly(ethylene glycol) coated MWCNTs do not induce a heat shock response (HSR) in GBM cell lines. Activation of the HSR in GBM cells via exposure to sub-ablative temperatures or short term treatment with an inhibitor of heat shock protein 90 (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG)), induces a protective heat shock response that results in thermotolerance and protects against CNMTT. Finally, we evaluate the potential for CNMTT to treat GBM multicellular spheroids. These data provide pre-clinical insight into key parameters needed for translation of CNMTT including nanoparticle delivery, cytotoxicity, and efficacy for treatment of thermotolerant GBM.

show abstract

Section: Resultssupporting

confidence: 92%

Photothermal Therapy of Glioblastoma Multiforme Using Multiwalled Carbon Nanotubes Optimized for Diffusion in Extracellular Space

Eldridge

Bernish

Fahrenholtz

et al. 2016

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…These nanotubes absorb NIR light from an external laser source without the need for an additional photoactivator, resulting in radiative relaxation and hyperthermic tumor ablation. [ 145 ] A similar concept has been demonstrated for intracranial tumors using an external NIR source that interacts with hybrid silica-gold nanoshells. [ 39 ] Direct neurosurgical investigation of this technology is currently expanding, with lasers positioned either adjacent to an open resection cavity, or intracranially using long needles similar to those for laser-induced interstitial thermotherapy (LITT).…”

Section: Nanomaterials Tissue Ablation–creative Approaches To mentioning

confidence: 96%

Bionanotechnology and the Future of Glioma

et al. 2015

View full text Add to dashboard Cite

Designer nanoscaled materials have the potential to revolutionize diagnosis and treatment for glioma. This review summarizes current progress in nanoparticle-based therapies for glioma treatment including targeting, drug delivery, gene delivery, and direct tumor ablation. Preclinical and current human clinical trials are discussed. Although progress in the field has been significant over the past decade, many successful strategies demonstrated in the laboratory have yet to be implemented in human clinical trials. Looking forward, we provide examples of combined treatment strategies, which harness the potential for nanoparticles to interact with their biochemical environment, and simultaneously with externally applied photons or magnetic fields. We present our notion of the “ideal” nanoparticle for glioma, a concept that may soon be realized.

show abstract

“…Furthermore, this protocol could eliminate glioma CSCs, both drug-sensitive and drug-resistant glioma cells due to the broad-spectrum absorption of CNTs by gliomas. In contrast, normal cells were merely affected, demonstrating the lower uptake of CNTs ( Santos et al, 2014 ). Hyperthermia in glioma treatment remains controversial because it is technically difficult to impose a lethal dose of heat to all cell populations within the glioma mass.…”

Section: Emerging Strategies Using Nanocarriersmentioning

confidence: 99%

Targeted Nanotechnology in Glioblastoma Multiforme

et al. 2017

View full text Add to dashboard Cite

Gliomas, and in particular glioblastoma multiforme, are aggressive brain tumors characterized by a poor prognosis and high rates of recurrence. Current treatment strategies are based on open surgery, chemotherapy (temozolomide) and radiotherapy. However, none of these treatments, alone or in combination, are considered effective in managing this devastating disease, resulting in a median survival time of less than 15 months. The efficiency of chemotherapy is mainly compromised by the blood-brain barrier (BBB) that selectively inhibits drugs from infiltrating into the tumor mass. Cancer stem cells (CSCs), with their unique biology and their resistance to both radio- and chemotherapy, compound tumor aggressiveness and increase the chances of treatment failure. Therefore, more effective targeted therapeutic regimens are urgently required. In this article, some well-recognized biological features and biomarkers of this specific subgroup of tumor cells are profiled and new strategies and technologies in nanomedicine that explicitly target CSCs, after circumventing the BBB, are detailed. Major achievements in the development of nanotherapies, such as organic poly(propylene glycol) and poly(ethylene glycol) or inorganic (iron and gold) nanoparticles that can be conjugated to metal ions, liposomes, dendrimers and polymeric micelles, form the main scope of this summary. Moreover, novel biological strategies focused on manipulating gene expression (small interfering RNA and clustered regularly interspaced short palindromic repeats [CRISPR]/CRISPR associated protein 9 [Cas 9] technologies) for cancer therapy are also analyzed. The aim of this review is to analyze the gap between CSC biology and the development of targeted therapies. A better understanding of CSC properties could result in the development of precise nanotherapies to fulfill unmet clinical needs.

show abstract

Sequential Administration of Carbon Nanotubes and Near-Infrared Radiation for the Treatment of Gliomas

Cited by 33 publications

References 26 publications

Photothermal Therapy of Glioblastoma Multiforme Using Multiwalled Carbon Nanotubes Optimized for Diffusion in Extracellular Space

Photothermal Therapy of Glioblastoma Multiforme Using Multiwalled Carbon Nanotubes Optimized for Diffusion in Extracellular Space

Bionanotechnology and the Future of Glioma

Targeted Nanotechnology in Glioblastoma Multiforme

Contact Info

Product

Resources

About